Are novel oral oncolytics underdosed in obese patients?

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

(2023) Maud B. A. van der Kleij et al.   CLINICAL PHARMACOKINETICS

Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss

(2022) Sjaak Pouwels et al.   BMC Endocrine Disorders

Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes

(2022) Tan Zhang et al.   Expert Opinion on Drug Metabolism & Toxicology

Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update

(2021) Jennifer J. Griggs et al.   JOURNAL OF CLINICAL ONCOLOGY

Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas

(2021) Elizabeth G. Gibson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs

(2020) Dr. Julie M. Janssen et al.   THERAPEUTIC DRUG MONITORING

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors

(2020) Erjian Wang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Exposure‐response analyses of anaplastic lymphoma kinase inhibitors crizotinib and alectinib in non‐small‐cell lung cancer patients

(2020) Stefanie L. Groenland et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma

(2019) Julie M. Janssen et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer

(2019) M. van Nuland et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma

(2018) Steven Lacy et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology

(2018) Stefanie L. Groenland et al.   CLINICAL PHARMACOKINETICS

Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters

(2018) Cornelis Smit et al.   Expert Opinion on Drug Metabolism & Toxicology

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS

(2018) Remy B. Verheijen et al.   THERAPEUTIC DRUG MONITORING

Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients

(2017) E. Carton et al.   EUROPEAN JOURNAL OF CANCER

Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma

(2017) Merel van Nuland et al.   THERAPEUTIC DRUG MONITORING

Obesity and morbid obesity associated with higher odds of hypoalbuminemia in adults without liver disease or renal failure

(2017) Rana H Mosli et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

(2016) Daniele Ouellet et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

(2016) R. B. Verheijen et al.   CLINICAL CANCER RESEARCH

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients

(2016) Huixin Yu et al.   CLINICAL PHARMACOKINETICS

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer

(2015) Kim N. Chi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

(2014) N A G Lankheet et al.   BRITISH JOURNAL OF CANCER

American Society of Clinical Oncology Position Statement on Obesity and Cancer

(2014) Jennifer A. Ligibel et al.   JOURNAL OF CLINICAL ONCOLOGY

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry

(2012) N. A. G. Lankheet et al.   BIOMEDICAL CHROMATOGRAPHY

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

(2012) F. Guilhot et al.   HAEMATOLOGICA

Pharmacokinetics of sunitinib in an obese patient with a GIST

(2009) I. M. E. Desar et al.   ANNALS OF ONCOLOGY

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

(2008) Divya Menon-Andersen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY